Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate

Biochemical and Biophysical Research Communications

Volumn 301, Issue 4, 2003, Pages 1062-1068

  Chang, Li Kwan ^a   Wei, Ta Tung ^b   Chiu, Ya Fang ^b   Tung, Chao Ping ^b   Chuang, Jian Ying ^b   Hung, Shang Kai ^b   Li, Ching ^c   Liu, Shih Tung ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN EBNA 1; PROTEIN RTA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; DNA MICROARRAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMEDIATE EARLY GENE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LYSIS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; VIRUS INHIBITION;

HUMAN HERPESVIRUS 4;

EID: 0037459049     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00067-6     Document Type: Article

References (34)

1. Balasubramanian S., Efimova T., Eckert R.L. Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. J. Biol. Chem. 277:2000;1828-1836.
2. Brockmeyer N.H., Pohl G., Mertins L. Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection. Eur. J. Med. Res. 2:1997;133-135.
3. Chang L.-K., Liu S.-T. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res. 28:2000;3918-3925.
4. Chang P.J., Chang Y.S., Liu S.T. Role of Rta in the translation of bicistronic BZLF1 of Epstein-Barr virus. J. Virol. 72:1998;5128-5136.
5. Chen C.C., Shieh B., Jin Y.T., Liau Y.E., Huang C.H., Liou J.T., Wu L.W., Huang W., Young K.C., Lai M.D., Liu H.S., Li C. Microarray profiling of gene expression patterns in bladder tumor cells treated with genistein. J. Biomed. Sci. 8:2001;214-222.
6. Chen L.W., Lin L.S., Chang Y.S., Liu S.T. Functional analysis of EA-D of Epstein-Barr virus. Virology. 211:1995;593-597.
7. Datta A.K., Colby B.M., Shaw J.E., Pagano J.S. Acyclovir inhibition of Epstein-Barr virus replication. Proc. Natl. Acad. Sci. USA. 77:1980;5163-5166.
8. Ernberg I., Andersson J. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J. Gen. Virol. 67:1986;2267-2272.
9. Field A.K., Biron K.K. The end of innocence revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7:1994;1-13.
10. Henle G., Henle W. Observations on childhood infections with the Epstein-Barr virus. J. Infect. Dis. 121:1970;303-310.
11. Holley-Guthrie E.A., Quinlivan E.B., Mar E.C., Kenney S. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:1990;3753-3759.
12. Hopwood P.A., Brooks L., Parratt R., Hunt B.J., Maria B., Alero T.J., Magdi Y., Crawford D.H. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation. 74:2002;194-202.
13. Ikigai H., Toda M., Okubo S., Hara Y., Shimamura T. Relationship between the anti-hemolysin activity and the structure of catechins and theaflavins. Nippon Saikingaku Zasshi. 45:1990;913-919.
14. Jankun J., Keck R.W., Skrzypczak-Jankun E., Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 57:1997;559-563.
15. Jones J.F., Shurin S., Abramowsky C., Tubbs R.R., Sciotto C.G., Wahl R., Sands J., Gottman D., Katz B.Z., Sklar J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N. Engl. J. Med. 318:1988;733-741.
16. Liberto M., Cobrinik D. Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Lett. 154:2000;151-161.
17. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB. Mol. Pharmacol. 52:1997;465-472.
18. Mueller N., Evans A., Harris N.L., Comstock G.W., Jellum E., Magnus K., Orentreich N., Polk B.F., Vogelman J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N. Engl. J. Med. 320:1989;689-695.
19. Mukoyama A., Ushijima H., Nishimura S., Koike H., Toda M., Hara Y., Shimamura T. Inhibition of rotavirus and enterovirus infections by tea extracts. Jpn. J. Med. Sci. Biol. 44:1991;181-186.
20. Nakane H., Ono K. Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry. 29:1990;2841-2845.
21. Nakayama M., Suzuki K., Toda M., Okubo S., Hara Y., Shimamura T. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 21:1993;289-299.
22. Niederman J.C., McCollum R.W., Henle G., Henle W. Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. J. Am. Med. Assoc. 203:1968;205-209.
23. Niedobitek G., Hamilton-Dutoit S., Herbst H., Finn T., Vetner M., Pallesen G., Stein H. Identification of Epstein-Barr virus-infected cells in tonsils of acute infectious mononucleosis by in situ hybridization. Human Pathol. 20:1989;796-799.
24. Okubo S., Toda M., Hara Y., Shimamura T. Antifungal and fungicidal activities of tea extract and catechin against trichophyton. Nippon Saikingaku Zasshi. 46:1991;509-514.
25. Porcu P., Eisenbeis C.F., Pelletier R.P., Davies E.A., Baiocchi R.A., Roychowdhury S., Vourganti S., Nuovo G.J., Marsh W.L., Ferketich A.K., Henry M.L., Ferguson R.M., Caligiuri M.A. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 100:2002;2341-2348.
26. Rodriguez A., Jung E.J., Flemington E.K. Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycle-inducing agents. J. Virol. 75:2001;4482-4489.
27. Schwarzmann F., Jager M., Hornef M., Prang N., Wolf H. Epstein-Barr viral gene expression in B-lymphocytes. Leuk. Lymphoma. 30:1998;123-129.
28. Su I.J., Chen R.L., Lin D.T., Lin K.S., Chen C.C. Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan. Am. J. Pathol. 144:1994;1219-1225.
29. Su I.J., Hsieh H.C., Lin K.H., Uen W.C., Kao C.L., Chen C.J., Cheng A.L., Kadin M.E., Chen J.Y. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 77:1991;799-808.
30. Takase K., Kelleher C.A., Terada N., Jones J.F., Lucas J.J., Gelfand E.W. Dissociation of EBV genome replication and host cell proliferation in anti-IgG-stimulated Akata cells. Clin. Immunol. Immunopathol. 81:1996;168-174.
31. Taniguchi S., Imayoshi Y., Kobayashi E., Takamatsu Y., Ito H., Hatano T., Sakagami H., Tokuda H., Nishino H., Sugita D., Shimura S., Yoshida T. Production of bioactive triterpenes by Eriobotrya japonica calli. Phytochemistry. 59:2002;315-323.
32. Toda M., Okubo S., Ikigai H., Suzuki T., Suzuki Y., Hara Y., Shimamura T. The protective activity of tea catechins against experimental infection by Vibrio cholerae O1. Microbiol. Immunol. 36:1992;999-1001.
33. Wolf H., zur Hausen H., Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat. New Biol. 244:1973;245-247.
34. Yamaguchi K., Honda M., Ikigai H., Hara Y., Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 53:2002;19-34.